StockData
Clearmind Medicine Inc. logo

Clearmind Medicine Inc. (CMND) stock

CMNDNasdaqPharmaceutical PreparationsFiscal year ends October 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Score 5/30
$3.45−0.73 (-17.52%)

Close on Nov 17, 2026Market cap $545.36KP/E –Yield –

Clearmind Medicine r&d expenses

Research and development expenses are spending on new products and technology.

Clearmind Medicine's R&D Expenses for the twelve months ending Jul 31, 2026 was $2.30M, up 8.2% year over year. For fiscal 2025 it was $2.06M, up 48.7% from the year before. The highest annual figure on record is $3.08M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Oct 31, 2025$2.06M+48.7%
FY2024Oct 31, 2024$1.38M-10.5%
FY2023Oct 31, 2023$1.54M-49.9%
FY2022Oct 31, 2022$3.08M+550.5%
FY2021Oct 31, 2021$473.65K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jul 31, 2026$588.96K-18.5%
Q2 FY2026CQ1 2026Apr 30, 2026$646.71K+43.1%
Q1 FY2026CQ4 2025Jan 31, 2026$640.49K+38.8%
Q4 FY2025CQ3 2025Oct 31, 2025$420.18K-13.6%
Q3 FY2025CQ2 2025Jul 31, 2025$723.05K+109.0%
Q2 FY2025CQ1 2025Apr 30, 2025$451.86K+39.9%
Q1 FY2025CQ4 2024Jan 31, 2025$461.44K+3520.3%
Q4 FY2024CQ3 2024Oct 31, 2024$486.49K+29.7%
Q3 FY2024CQ2 2024Jul 31, 2024$345.88K+31.0%
Q2 FY2024CQ1 2024Apr 30, 2024$322.96K+1.7%
Q1 FY2024CQ4 2023Jan 31, 2024$12.75K-97.8%
Q4 FY2023CQ3 2023Oct 31, 2023$375.07K-67.7%
Q3 FY2023CQ2 2023Jul 31, 2023$263.95K–
Q2 FY2023CQ1 2023Apr 30, 2023$317.57K–
Q1 FY2023CQ4 2022Jan 31, 2023$587.63K–
Q2 FY2022CQ1 2022Apr 30, 2022$1.16M–

More Clearmind Medicine figures

See a number that looks wrong?